LALPATHLAB share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on LALPATHLAB. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for LALPATHLAB is 93 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for LALPATHLAB is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

LALPATHLAB sits in Healthcare (mid cap), indicative market cap ~28,595 cr (indicative), ISIN INE600L01024. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on Dr. Lal Path Labs Ltd.: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on LALPATHLAB is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, Dr. Lal Path Labs Ltd. sits in the Scanned tier with a setup score of 81/100 (technical 100, fundamental 60). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 25 LALPATHLAB earnings calls going back to 2020-06-30, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

Dr. Lal Path Labs Ltd. reported a net profit of Rs 132 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -15.0% year on year. The figure is from the company's official NSE filing.

Dr. Lal Path Labs Ltd. reported revenue of Rs 703 cr for Q4 FY26. That is +16.6% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives Dr. Lal Path Labs Ltd.'s Q4 FY26 result a Result Pulse of 68 out of 100, with a verdict of Sales acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Dr. Lal Path Labs Ltd.'s two most material recent disclosures are an investor meet dated 17 Jul 2026, "Schedule of meet", and a press release dated 17 Jul 2026, "General Updates - Received an appellant order from Income…". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Dr. Lal Path Labs Ltd. filed a dividend disclosure on 25 Jun 2026, filed as "Dividend - Rs 4 Per Share". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Dr. Lal Path Labs Ltd.'s most recent board-meeting disclosure on record dated 01 Jul 2026 reads "Notice of Annual General Meeting to be held on July 25, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.

Dr. Lal Path Labs Ltd. filed a credit-rating disclosure on 25 Mar 2026, recorded with the exchange as "Credit Rating- Revision (Upgraded from CARE AA; Stable to CARE AA+; Stable)". The detail sits in the linked filing on the BazaarBaazi stock page. A rating action is an agency view on debt, separate from the share price.